Zitate und weiterführende Literatur
Arnold G, Tatsch K, Oertel WH et al. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. J Neural Transm Suppl 1994; 42: 111–118
Benamer TS, Patterson J, Grosset DG et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000; 15: 503–510
Berg D, Becker G, Zeiler B et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026–1031
Braak H, Braak E. Pathoanatomy of Parkinson's disease. Journal of Neurology 2000; 247: 3–10
Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 Suppl 3: III/1–III/5
Buck A, Westera G, Sutter M, Albani C, Kung HF, von Schulthess GK. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J Nucl Med 1995; 36: 1196–1200
Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004; 19: 1175–1182
Comella CL. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 2003; 3: 173–180
Csoti I, Warmuth-Metz M, Solymosi L, Becker DG, Fornadi F, Naumann M. [Differentiation of atypical Parkinson syndrome and delineation from idiopathic Parkinson syndrome with routine magnetic resonance tomography]. Nervenarzt 2004; 75: 128–134
Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149: 443–454
de Rijk MC, Launer LJ, Berger K et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: 21–23
Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908
Diener and HC et al. Leitlinien der Deutschen Gesellschaft für Neurologie. Leitlinien für Diagnostik und Therapie in der Neurologie. Georg Thieme Verlag 2005; 48–71
Eggert K, Odin P, Gasser T, Meinertz T, Strasser R, Osterspey A, Deuschl G, Oertel and W. Deutsches Ärzteblatt 2005;1-2: 102, A-30 / B-22 / C-20
El Sharkawi A, Ramig L, Logemann JA et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002; 72: 31–36
Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2005; 86: 626–632
Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004; 351: 2509–2518
Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1988; 51: 745–752
Gilman S, Low PA, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998; 74: 189–192
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442
Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinico-pathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140–148
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992a; 55: 181–184
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]. J Neurol Neurosurg Psychiatry 1992b; 55: 181–184
Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497–1499
Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000; 57: 369–372
Jöbges M, Heuschkel G, Pretzel C, Illhardt C, Renner C, Hummelsheim H. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1682–1687
Langston JW. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 1998; 44: S45–S52
Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1–9
Marti-Masso JF, Poza JJ, Lopez dM. Drugs inducing or aggravating parkinsonism: a review. Therapie 1996; 51: 568–577
McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–1124
Nieuwboer A, Kwakkel G, Rochester L et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007; 78: 134–140
Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999; 340: 757–763
Plotkin M, Amthauer H, Klaffke S et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112: 677–692
Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004; 111: 201–216
Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord. 2001; 16: 79–83
Schapira AH. Pathogenesis of Parkinson's disease. Baillieres Clin Neurol 1997; 6: 15–36
Schrag A, Ben Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529–534
Schrag A, Good CD, Miszkiel K et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697–702
Schrag A, Kingsley D, Phatouros C et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998; 65: 65–71
Schuurman AG, van den AM, Ensinck KT et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002; 58: 1501–1504
Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord. 2004; 19: 1445–1449
Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003; 60: 74–77
Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002; 109: 191–196
Author information
Authors and Affiliations
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Buhmann, C. Morbus Parkinson: Klinik, Differenzialdiagnostik und Therapie. Von Priv.-Doz. Dr. med. Carsten Buhmann, Universitätsklinikum Eppendorf, Hamburg. focus neurogeriatrie 1, 33–39 (2007). https://doi.org/10.1007/s12151-008-0079-9
Issue Date:
DOI: https://doi.org/10.1007/s12151-008-0079-9